Børsen
With the purchase of the American biotech company Profoundbio for 12.5 billion kroner, Genmab has secured a drug that the company itself believes can achieve annual sales of more than 1 billion dollars, equivalent to 6.9 billion kroner.
With the purchase of the American biotech company Profoundbio for 12.5 billion kroner, Genmab has secured a drug that the company itself believes can achieve annual sales of more than 1 billion dollars, equivalent to 6.9 billion kroner.